Response to ‘Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis’

由 Vastesaeger, Nathan, Fautrel, Bruno, Smolen, Josef
發表在 Arthritis Res Ther (2015)

Response to the commentary 'Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind'

由 Vander Cruyssen, Bert, Durez, Patrick, Westhovens, Rene, Vastesaeger, Nathan, Geldhof, Anja, De Keyser, Filip
出版 2006

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study

由 Baranauskaite, Asta, Raffayová, Helena, Kungurov, NV, Kubanova, Anna, Venalis, Algirdas, Helmle, Laszlo, Srinivasan, Shankar, Nasonov, Evgeny, Vastesaeger, Nathan
出版 2011

Effectiveness and Safety of Infliximab in Two Cases of Severe Chondrocalcinosis: Nine Years of Follow-Up

由 Bruges-Armas, Jácome, Bettencourt, Bruno F., Couto, Ana R., Lima, Manuela, Rodrigues, Ana M., Vastesaeger, Nathan, Brown, Matthew A.
發表在 Case Rep Rheumatol (2014)

The epidemiology of ankylosing spondylitis and the commencement of anti‐TNF therapy in daily rheumatology practice

由 Cruyssen, Bert Vander, Ribbens, Clio, Boonen, Annelies, Mielants, Herman, de Vlam, Kurt, Lenaerts, Jan, Steinfeld, Serge, Van den Bosch, Filip, Dewulf, Lode, Vastesaeger, Nathan
出版 2007

Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study

由 Combe, Bernard, Dasgupta, Bhaskar, Louw, Ingrid, Pal, Sarvajeet, Wollenhaupt, Jürgen, Zerbini, Cristiano A F, Beaulieu, Andre D, Schulze-Koops, Hendrik, Durez, Patrick, Yao, Ruji, Vastesaeger, Nathan, Weng, Haoling H
出版 2014

Predicting the outcome of ankylosing spondylitis therapy

由 Vastesaeger, Nathan, van der Heijde, Désirée, Inman, Robert D, Wang, Yanxin, Deodhar, Atul, Hsu, Benjamin, Rahman, Mahboob U, Dijkmans, Ben, Geusens, Piet, Vander Cruyssen, Bert, Collantes, Eduardo, Sieper, Joachim, Braun, Jürgen
出版 2011

Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity

由 Cruyssen, Bert Vander, Van Looy, Stijn, Wyns, Bart, Westhovens, Rene, Durez, Patrick, Van den Bosch, Filip, Mielants, Herman, De Clerck, Luc, Peretz, Ann, Malaise, Michel, Verbruggen, Leon, Vastesaeger, Nathan, Geldhof, Anja, Boullart, Luc, De Keyser, Filip
出版 2006

DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab...

由 Vander Cruyssen, Bert, Van Looy, Stijn, Wyns, Bart, Westhovens, Rene, Durez, Patrick, Van den Bosch, Filip, Veys, Eric M, Mielants, Herman, De Clerck, Luc, Peretz, Anne, Malaise, Michel, Verbruggen, Leon, Vastesaeger, Nathan, Geldhof, Anja, Boullart, Luc, De Keyser, Filip
出版 2005

Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab

由 Vastesaeger, Nathan, Kutzbach, Abraham Garcia, Amital, Howard, Pavelka, Karel, Lazaro, María Alicia, Moots, Robert J., Wollenhaupt, Jürgen, Zerbini, Cristiano A. F., Louw, Ingrid, Combe, Bernard, Beaulieu, Andre, Schulze-Koops, Hendrik, Dasgupta, Bhaskar, Fu, Bo, Huyck, Susan, Weng, Haoling H., Govoni, Marinella, Durez, Patrick
發表在 Rheumatology (Oxford) (2016)